Author(s): Edelman MJ, Gandara DR
Abstract Share this page
Abstract A number of new drugs and drug classes have recently become available for clinical testing which demonstrate significant antitumor activity in non-small cell lung cancer. The preclinical rationale, mechanism of action, toxicity profile and results of early trials of paclitaxel, docetaxel, edatrexate, CPT-11, topotecan, vinorelbine and gemcitabine in non-small cell lung cancer are reviewed.
This article was published in Cancer Chemother Pharmacol
and referenced in Journal of Nanomedicine & Nanotechnology